Several predictive candidates were previously tested in oncology: tissue biomarkers (VEGFA, VEGFR2, CAIX, HIF2α, and hERG1) [13], molecular biomarkers (HIF1α, VEGFA, VEGF single nucleotide polymorphisms, transcriptomic signature, microRNA signature, angiotensinogen promoter methylation) [14, 15], circulating biomarkers (plasma levels of VEGFA, CAIX, Tie2, and bevacizumab trough concentration) [16–19], or clinical factors (hypertension) [20]. This evidence concerns the gene TEK and hypertensive disorder.